Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
2022 · The Journal of Prevention of Alzheimer s Disease · 1,228 citations
https://doi.org/10.14283/jpad.2022.30
A
Alfred Sandrock
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
87
Papers
16.8K
Citations
35
h-index
53
i10-index
Alfred Sandrock is an academic researcher from Biogen (United States). The author has contributed to research in topics: Alzheimer's disease research and treatments & Multiple Sclerosis Research Studies & Polyomavirus and related diseases. The author has an h-index of 35, co-authored 74 publications.
Papers by this author
worksNusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
2019 · Neuromuscular Disorders · 612 citations
https://doi.org/10.1016/j.nmd.2019.09.007
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
2023 · The Journal of Prevention of Alzheimer s Disease · 22 citations
https://doi.org/10.14283/jpad.2023.6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat